Next‐Generation Cancer Therapeutics: Revolutionizing Treatment with Precision Medicine and Immunotherapy

Cancer remains one of the leading causes of death worldwide, with traditional therapies like surgery, chemotherapy, and radiation being limited by toxicity and resistance. Recent breakthroughs in antibody-mediated therapies, precision medicine, and immunotherapies are reshaping the cancer treatment landscape. Monoclonal antibodies (mAbs), immune checkpoint inhibitors, and chimeric antigen receptor T-cell (CAR-T) therapies have proven to be highly effective, offering more targeted, less toxic alternatives to traditional treatments. Alongside these innovations, the integration of genomic profiling and next-generation sequencing (NGS) has paved the way for precision oncology, where therapies are tailored to the unique genetic makeup of a patient’s cancer. However, challenges such as tumor heterogeneity, therapy resistance, and immunotoxicity persist. This review discusses the mechanisms, clinical successes, and challenges associated with antibody-mediated therapies and precision medicine, as well as emerging treatment modalities. We also highlight the role of artificial intelligence (AI) in accelerating cancer research and improving therapeutic outcomes.